Navigation Links
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain

an, Chairman and CEO of YM BioSciences. "We look forward to completing a detailed analysis of the numerous secondary endpoints and safety data from this study to extend the information we will make available. These results will also be used to enhance the design of the additional Phase II trial that we are planning for the U.S. as well as the eventual Phase III trial."

Clinical Trial Design

The Phase IIb clinical study (DLXLEF-AP4) was a 2-part, multi-center study to evaluate the efficacy, safety and tolerability of repeated, self-titrated inhalation of AeroLEF(TM) for the treatment of acute post-operative pain following orthopedic surgery. Part 1 of the study was a 21 patient open-label, lead-in study to ensure consistency of AeroLEF(TM) administration across study sites. Results of Part I of the Phase IIb study were presented at the 2006 American Society of Anesthesiologists (ASA) Annual Meeting in Chicago, IL.

Part 2 was a 99 patient randomized, placebo-controlled study. The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when the patient reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to seve
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... WIRE)--Jun 5, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: ... and commercializing small,molecule drugs to treat severe ... conference call at 2:30 p.m. (EST) today ... at the annual meeting of the,American Society ...
... Dosing Results in Improved Tolerance,and Evidence of ... MENLO PARK, California U.S.A. June 04,2007-ChemGenex Pharmaceuticals ... of data from its Quinamed (amonafide,dihydrochloride) phase ... optimised dose of Quinamed in heavily,pre-treated patients ...
Cached Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
(Date:4/24/2014)... State University researcher has found a relationship between motor ... autism spectrum disorder in very young children. , ... show a direct relationship between motor skills and autism ... skills should be included in treatment plans for young ... in OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... a global,provider of products and services that improve the ... for the medical technology company that will,be formed through ... , The new company will ... the company will offer to improve the safety and ...
... The DRE VSE Series includes a variety of affordable, dependable surgery ... ... (Vocus) February 16, 2009 -- DRE Veterinary — a ... VSE Series, a line of surgical and exam tables. All DRE ...
... (February 15, 2009)P&G Beauty & Grooming scientists are presenting ... that offers evidence of science,s role in evolving beauty ... observes the 200th anniversary of Charles Darwin,s birth, affording ... advanced science and technology to help individuals feel and ...
... re-newed demand for affordable drug rehabs - Mountainside Drug Rehab Center ... an inpatient substance abuse treatment curriculum that has been replicated by ... ... (PRWEB) February 15, 2009 -- The economy has been under extraordinary ...
... ROCK HILL, S.C., Feb. 14 A York County jury ... child who suffered a brain injury at birth. The award ... at fault when it assigned a nurse trainee to monitor ... with nausea and vomiting. The nurse misread fetal heart monitoring ...
... males face higher risk of fathering children with medical problems, ... wasn,t all that long ago that any suggestion that a ... father children sooner rather than later, would have been given ... of evidence suggests that as men get older, fertility can ...
Cached Medicine News:Health News:Cardinal Health Announces New Name for Spinoff Company 2Health News:Cardinal Health Announces New Name for Spinoff Company 3Health News:Cardinal Health Announces New Name for Spinoff Company 4Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 2Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 3Health News:DRE Veterinary Unveils Line of Surgical and Exam Tables 4Health News:Beauty and grooming science evolves 2Health News:Beauty and grooming science evolves 3Health News:Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA 2Health News:Men Must Contend With a Biological Clock, Too 2Health News:Men Must Contend With a Biological Clock, Too 3
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
Medicine Products: